SCHEMBL9967942

SCHEMBL9967942

Nc1cccnc1NS(=O)(=O)c1cccs1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.58
NFKBIA P25963 1/20 0.56
RELA Q04206 1/20 0.56
GLO1 Q04760 1/20 0.56
TSHR P16473 3/20 0.54
LMNA P02545 1/20 0.54
TP53 P04637 1/20 0.54
ALOX15 P16050 1/20 0.54
OPRK1 P41145 1/20 0.54
HTT P42858 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
TLR9 Q9NR96 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
GAA P10253 1/20 0.54
MMP2 P08253 2/20 0.51
ALDH1A1 P00352 5/20 0.50
KMT2A Q03164 4/20 0.50
CCR2 P41597 1/20 0.49
HPGD P15428 3/20 0.48
MEN1 O00255 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9967883 0.78 CCR2 (0.49) KDM4ETSHRLMNAHTTNPSR1
SCHEMBL9967998 0.78 PKM (0.56) KDM4ENFKBIARELAGLO1TSHR
SCHEMBL8840340 0.78 KDM4E (0.69) KDM4ENFKBIARELAGLO1TSHR
SCHEMBL6608230 0.78 KDM4E (0.56) KDM4ENFKBIARELAGLO1TSHR
SCHEMBL1415780 0.78 NFKBIA (0.68) KDM4ENFKBIARELAGLO1TSHR
SCHEMBL6180658 0.75 CCR4 (0.69) KDM4ENFKBIARELAGLO1TSHR
SCHEMBL10878905 0.75 ALDH1A1 (0.61) KDM4ENFKBIARELAGLO1TSHR
SCHEMBL10143539 0.74 CA2 (0.49) NFKBIARELATDP1KMT2ACCR2
SCHEMBL4723109 0.74 KDM4E (1.00) KDM4ENFKBIARELAGLO1TSHR
Cycloheptane SCHEMBL4200303 0.72 KDM4E (0.47) KDM4ENFKBIARELAGLO1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2955173-B1 1,2-BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN INC (US) 2017-10-04 EP disclosed
US-9603834-B2 1,2- bis-sulfonamide derivatives as chemokine receptor modulators ALLERGAN, INC. (US) 2017-03-28 US disclosed
US-9603834-B2 1,2- bis-sulfonamide derivatives as chemokine receptor modulators ALLERGAN, INC. (US) 2017-03-28 US disclosed
US-20160228407-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. 2016-08-11 US disclosed
US-20160228407-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. 2016-08-11 US disclosed
EP-2955173-A1 NOVEL 1,2-BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2015-12-16 EP disclosed
EP-2651901-B1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN INC (US) 2015-05-27 EP disclosed
US-20140221351-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2014-08-07 US disclosed
US-20140221351-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2014-08-07 US disclosed
US-8729066-B2 1,2- bis-sulfonamide derivatives as chemokine receptor modulators ALLERGAN, INC. (US) 2014-05-20 US disclosed
US-8729066-B2 1,2- bis-sulfonamide derivatives as chemokine receptor modulators ALLERGAN, INC. (US) 2014-05-20 US disclosed
US-20140051682-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2014-02-20 US disclosed
US-20140051682-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2014-02-20 US disclosed
US-8580779-B2 1,2-bis-sulfonamide derivatives as chemokine receptor modulators ALLERGAN, INC. (US) 2013-11-12 US disclosed
US-8580779-B2 1,2-bis-sulfonamide derivatives as chemokine receptor modulators ALLERGAN, INC. (US) 2013-11-12 US disclosed
WO-2012082633-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2012-06-21 WO disclosed
US-20120157444-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2012-06-21 US disclosed
US-20120157444-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228407-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS CXCR2, CCR2, CX3CR1 KDM4E 4794/4885NFKBIA 413/4885RELA 683/4885
US-20140051682-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS CXCR2, CCR2, CX3CR1 KDM4E 4794/4885NFKBIA 413/4885RELA 683/4885
US-20140221351-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS CXCR2, CCR2, CX3CR1 KDM4E 4794/4885NFKBIA 413/4885RELA 683/4885
US-20120157444-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS CXCR2, CCR2, CX3CR1 KDM4E 4794/4885NFKBIA 413/4885RELA 683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.